# Hepatitis C GP CME 2010


#### **Edward Gane**

New Zealand Liver Transplant Unit Auckland City Hospital


# 

Over 3 Million Americans Are Infected With the **Stealth Virus**. Most Don't Know It.


### Trends in Hepatitis C Prevalence of HCV infection in NZ



#### **Epidemiology of Hepatitis C Risk Factors for HCV infection**




#### **Trends in Hepatitis C Incidence of HCV in Australia**




Dore et al. HCV Projections Working Group 2007

# **Chronic Hepatitis C - the Problem**


### **1. Falling prevalence but aging cohort**



Davis G, et al Liver Transpl 2003; 9: 331-8



# HCV Epidemiology and Trends Liver Cancer at Auckland Hospital 1990-2010 (n=848)



**HCV** diagnosis and staging Symptoms and Signs »Unhelpful as nonspecific until advanced cirrhosis Anti-HCV ELISA screening assay »Inexpensive (\$15), performed daily at all labs »Reflects HCV exposure, not active infection may persist after viral clearance Serum HCV RNA PCR assay »Expensive (\$250), performed weekly only at reference laboratories »Confirms active infection Liver Function Test »POOR marker of liver injury in HCV »Need liver biopsy or Fibroscan

# Fibroscan




#### Fibroscan


Painless, noninvasive
Takes 2-3 minutes
Performed in clinic
No sedation
No complications

 Measures 1/500 of liver (c.f. biopsy=1/50,000)
 Less sampling error






### Fibroscan in Chronic Hepatitis C



Ziol M. 2005 Hepatology;41:48-54

# **Natural History of Chronic Hepatitis C**



**Factors associated with rapid** progression to cirrhosis Alcohol > 5 drinks/day »Paralyses immune response to HCV Increases HCV replication + injury »Keep below ALAC guidelines »Nil if cirrhosis or on IFN Cannabis >2 joints per day »Cannabilloid receptors in liver »low dose may help with IFN tolerability Metabolic syndrome Immunosuppressed (HIV/transplant)

# Life-Style Advice Sexual Transmission


	<u>No.</u>	Follow-up	%Partner <i>⇒</i> HCV+
Mothers (contami			
Meisel,1995	(94)	15 years	0%
Power,1995	(393)	20 years	0.3%
<u>Haemophiliac (</u> cor			
Hallam,1993	(104)	16 years	0%
Bresters,1993	(50)	13 years	0%
Intravenous drug			
Zylerberg,1999	(1640)	12 years	0.2%
Vandelli,2004	(776)	10 years	0%

### Life-Style Advice Mother-to-infant Transmission


Author	(n)	follow-up	% children ⇔HCV RNA+
Lam,1992	(66)	12 months	6%
Ohito,1994	(54)	6 months	<b>5%</b>
Conte,2000	(370)	18 months	5.1%
Gibb,2000	(441)	18 months	6.7%

Breast feeding is safe

### Treatment of Chronic Hepatitis C Efficacy




### Treatment of Chronic Hepatitis C Efficacy



# Treatment of Hepatitis C Safety

- 1. Flue syndrome in 100%
- 2. Anorexia, weight loss in 100%
- 3. Insomnia in >90%
- 4. Bone marrow suppression in >50%
- **5.** Hypothyroidism in 5%
- 6. Depression/anxiety in 40%
  - Relationship/work problems
  - Suicide in 1%
  - Due to seratonin depletion from CNS
  - Prevented by SSRIs






Accept refer to clinic


15%

Suitable for IFN 10%











# **NEW THERAPUTIC APPROACHES**

# **Direct Acting Antivirals (DAAs)**





# Hepatitis C in New Zealand The Problem

50,000 have HCV infection
Additional 20 infected each week *»no vaccine*>2000 already have cirrhosis
60 deaths/transplants per year
only 1/10 have been treated



#### Hepatitis C in New Zealand The Solutions (1)

- + rate of progression to cirrhosis
   reduce alcohol, cannabis, obesity
   Treat with antiviral therapy
- **2.** New more effective, safer therapies
- **3.** Better access to treatment
  - » Increased hospital clinics
  - Shared care with General Practice
- Better awareness and ↑ earlier diagnosis of all at risk



#### **BLOOD ISSUES** *K*

 Hon Pete Hodgson, Minister of Health, 11.30 Tuesday, 5 December 2006

"A \$30 million package to provide one-off payments to an estimated 550 people is part of a way forward for people who were infected with hepatitis C through the New Zealand blood supply"

"In addition, the Government is providing \$5 million a year to improve access to and uptake of hepatitis C treatment services.

The HCV Treatment Advisory Group is being set up to assist the Ministry and DHBs improve services to all people with hepatitis C. The advisory group will include consumer, clinical and district health board representatives".

### **HCTAG Terms of Reference**

# • Aims

- Analyse existing delivery of hepatitis C treatment (nationwide stocktake of DHB HCV services)
- 2. Identify priority interventions that could improve services and patient outcome



#### **DHB Stocktake of HCV Treatment Services**


Questionaires sent to every DHB May 2007 »16 of 21 replied by 10 2007;
Analysed, returned to DHBs for review; »20 of 21 replied (not MidCentral)
Further analysis (Robyn Brown)

#### **Key Performance Indicators**

- Referral: what information
- First Assessment
- Treatment
- General Statistics
- Waiting Times
- Other


#### DHB Stocktake of HCV Treatment Services Important issues identified

29. If someone with hepatitis C is referred this week from their GP, what is the approximate waiting time for an initial specialist assessment at your hospital?



#### DHB Stocktake of HCV Treatment Services Important issues identified

32. What is the approximate time interval between receipt of initial referral from GP, to first time specialist appointment, to commencement of antiviral therapy?



Strategic Directions for Hepatitis C To improve access to and uptake of treatment services for hepatitis C

Submitted by HCTAG in May 2009 Approved by Minister in July 2009



This document is available on the Ministry of Health's website: http://www.moh.govt.nz



# Strategic Directions for Hepatitis C: 4 Key Action Areas

- 1. improving knowledge of HCV among primary health care providers
- 2. improving the knowledge of HCV prevalence in the New Zealand population and within high-risk groups
- 3. increasing percentage of all people with HCV who have had the disease diagnosed
- 4. improving HCV treatment services

#### Hepatitis C



### **On-line E-learning module GP & Practice Nurse Survey**

- 100% GPs and 92% Nurses felt their knowledge of HCV was poor
- 40% GPs and 39% Nurses were concerned about being infected from HCV+ patient





### Strategic Directions for Hepatitis C: Key Action Areas

- 1. improving knowledge of HCV among primary health care providers
- On-line E-learning module for all primary care providers

#### Hepatitis C



**On-line E-learning module GP & Nurse Survey Feedback on e-Learning tool** 1. On-line 2. Accessible from home 3. Easy to navigate and return to on multiple occasions 4. Brief 30-40min 5. Quiz at end 6. Qualify for CME points 7. Printable certificate

Hepatitis C



#### Hepatitis C E-Learning for GPs

LearnHealth F Hep C - Doctors

#### Welcome

Learn about hepatitis C by working through the five learning modules below. Gain 1 CME credit by passing the assessment, completing the evaluation and then printing your certificate.

Access a range of resources to support you in your day-to-day work.

Help on using this programme.


#### Learn About



#### Post-Learning Support



#### What is Hepatitis C?



Hepatitis means 'inflammation of the liver'. The infection may be either acute or chronic. Common causes of hepatitis are viruses or medicines (prescribed, recreational or complementary alternative medicines).

The hepatitis C virus (HCV) is an **CRNA** virus, a member of the **CD** flaviviridae family. As a single stranded RNA virus, HCV has a very high transcription error rate and produces 100 million mutations every day. As a result, every infected person carries hundreds of slightly different strains of virus (quasispecies). This rapidly changing virus evades attempts of protection by either vaccine or immunoglobulin preparations.

Over the last century, the virus has evolved into 6 phylogenetically different  $\square$  genotypes and 11 subtypes.

200 million people are
 infected with HCV 3% of the world's
 population

An estimated **45-50,000 New Zealanders** are currently infected with HCV

Number of Genotypes: 6

Number of Sub-types: 11

What Is Hepatitis C?

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Back Next


55

"

#### Hepatitis C Misconceptions

There are a number of misconceptions about hepatitis C.

#### Which of the following statements is true?




#### **Transmission Routes**

HCV is transmitted via blood. This occurs through a number of different routes:

- Injecting drug use (IDU) via infected equipment
- Body piercing or tattooing via infected needles
- Vertical transmission HCV positive mother to child
- Sexual contact via exposure to infected blood
- Blood transfusion via infected blood
- O Household transmission via infected toothbrushes or shavers
- Nosocomially via infected equipment, organs or blood
- Onknown.

The chart shows transmission routes of known New Zealand infections.



#### New Zealand Transmission Routes

What Is Hepatitis C?

#### 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15


< Back Next >

#### Health Care Worker Risks

Needlestick injuries are a risk many health care workers must deal with. However, the risk of infection from an HCV infected needlestick injury is very low (0.2%) compared with the risk from an HBV infected needle (10-20%).

Paul believes he contracted hepatitis C through a needlestick injury while working as a staff nurse at Auckland Hospital, almost 30 years ago.

Use the controls to hear what Paul has to say.



# Image: Second state of the second state of

#### Paul, staff nurse

8


Fortunately, New Zealand now practices higher standards of care. This risk is avoidable and practising standard precautions should eliminate any risk of an infection from an infected individual.

What is Hepatitis C?

#### 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

<Back Next>

#### Symptoms And Signs



Symptoms of chronic hepatitis C include both hepatic and non-hepatic symptoms:

- Certain non-hepatic symptoms including lethargy and low-mood are common to most individuals
- Hepatic signs are usually confined to individuals with Confined to individuals with Configuration in the second sec

Click and rollover the highlighted parts of the image to learn more about the symptoms and signs of hepatitis C in both acute and chronic phases.

#### Porphyria cutanea tarda (PCT)

Hepatitis C is thought to inhibit bilirubin metabolic pathways within the liver cell, leading to hepatic overproduction of porphyrins and skin vesicle formation. Blistering is precipitated by ultraviolet exposure and therefore usually presents on the face or hands.

Appropriate management of PCT involves protection from sunlight and trauma, avoidance of alcohol excess and venesection. Eradication of HCV infection by antiviral therapy is associated with long-term remission of this skin disorder.

#### If you rely on **symptoms and signs** to diagnose chronic hepatitis C infection, you will diagnose it **too late** to be useful.

Identifying Hepatitis C

#### 1 2 3 4 5 6 7 8 9 10 11 12 < Back

< Back Next >

#### 

#### Side Effects Of Treatment





Use the controls to pause or rewind the video. Click the Show Captions button to display text alternative.

**Treating Hepatitis C** 

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 < Bar

Back Next

# **Objectives of the 5 Learning Modules**

Discuss critical facts about hepatitis C	Virology, epidemiology, natural history,
Identify individuals at risk of carrying HCV	key questions, symptoms and signs
Diagnose individuals with suspected hepatitis C	Tests & results, pre/post- test discussions, referral
Support patients receiving treatment	Medications, treatment, managing side-effects
Discuss treatments available in the future	Future medications, shared care

# **CME Credits**

- You will receive 1 CME credit if you complete all of the following activities:
  - 1. Pass the assessment (20 questions) with a score of 70% or more
  - 2. Complete a brief course feedback form
  - 3. Print your certificate of achievement

# **GOES LIVE**

**RNZCGP Annual Meeting Christchurch 2<sup>nd</sup> September**